Instrument Interprets Cardiac Test

Both the i-Lynx and the cardiac STATus test were developed by Spectral Diagnostics, Inc. (Toronto, Canada). The cardiac STATus test is a rapid test that measures markers of myocardial infarction.

According to Spectral, the company previously identified a market need in rapid testing in the hospital setting, particularly in critical illness situations. Although visual read-outs are convenient and rapid, differences in interpretation, lack of a permanent record and integration with other hospital records have limited their usefulness. The i-Lynx is designed to change that.

"We are very pleased with the early market acceptance of the i-Lynx,” said Dr. Paul Walker, president and CEO of Spectral Diagnostics. "We have now placed these instruments in both new and existing customer hospitals. The need for hospitals to meet rapid cardiac marker testing guidelines remains strong, and the i-Lynx provides an innovative solution.”

Spectral Diagnostics is a developer of innovative technologies for rapid diagnostics that enable the early initiation of appropriate and targeted therapy. The company has also developed rapid diagnostics for sepsis.




Related Links:
Spectral